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identiﬁed 88 aspects as subunits of eight main domains. Agencies
show most similarities in the domain ‘organization’ (4 of 15
subunits), followed by ‘dissemination’ (2 of 9), ‘methods’ (2 of
20), ‘processes’ (1 of 11), and, scope’ (1 of 13). All subunits of
the domains ‘decision’, ‘implementation’ and ‘impact’ were dif-
ferent. Ranking in terms of productivity is misleading without
taking into account other aspects. CONCLUSIONS: We found
considerably more differences than similarities across agencies
and countries inﬂuenced by contextual aspects. This elementary
framework is intended to provide disaggregated and global com-
parative insight that may allow further progress in clariﬁcation
on the need for action regarding harmonization. By enlarging the
number of agencies assessed, our ﬁndings could facilitate the
communication between producers and users in an understand-
able, interpretable and transferable way.
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OBJECTIVES: The Single Technology Appraisal (STA) system
has attempted to shorten the process of assessment. As a
follow-up to a previous ISPOR poster, we sought to update the
database with since published STAs as well as conduct further
qualitative research and investigate the criticisms on the eco-
nomic aspects of the submissions. Discrepancies between ICERs
obtained by the manufacturer and the ERG group, and their
impact on outcomes were assessed. METHODS: A previously
developed database was updated with data from submissions
appraised between 6 December 2006 and 31 May 2008. Top-line
clinical data was extracted from the manufacturer submission,
evidence review group report, expert submission and the ﬁnal
appraisal determination. Further qualitative data was gathered to
capture criticisms on the economic aspects of the submissions.
Differences in ICER values between the manufacturer and the
ERG group were also collected. RESULTS: In total, 18 STAs
have been submitted to and appraised by NICE. Thirteen of the
18 submissions received positive guidance from NICE, recom-
mending the use of the drug in the NHS. Further investigation
into criticisms on the economic aspect revealed under-estimation
of costs, exclusion of relevant costs and/or adverse events and
concerns over the time horizon implemented resulting in an
under-estimation of the ICER, commonly leading to negative
guidance. Industry submissions reported ICERs ranging from
£4,726.00 to £44,600.00. Corresponding ICERs reported by the
ERG ranged from £8,500.00 to £458,000.00. The committee
provided positive guidance in approximately 50% of cases, even
though the ERG expressed concerns regarding aspects of the
economic model. CONCLUSIONS: Results demonstrated dis-
crepancies in ICERs between the manufacturer’s submission and
the ERG report. Fifty percent of the submissions received positive
guidance irrespective of concerns voiced by the ERG. Analyzing
criticisms on economic aspects of submissions alongside the ﬁnal
outcome will assist in educating manufacturers in the expecta-
tions of NICE.
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OBJECTIVES: Technology appraisal systems are used in many
countries to assess newly licensed drug treatments and devices.
Our objective was to identify the reasons underlying recent drug
appraisal decisions in four countries (England/Wales, Scotland,
Canada and Australia) where decisions differed between the
agencies. METHODS: Submissions appraised between 1 Novem-
ber 2005 and 31 May 2008 by NICE, SMC, CADTH and PBAC,
in England/Wales, Scotland, Canada and Australia respectively,
were searched for submissions with opposing decision outcomes.
We compared qualitatively and quantitatively the reasons for
rejection or recommendation for all drugs where decision out-
comes differed between HTA bodies. RESULTS: A total of 81
submissions were identiﬁed as having been appraised by two or
more of the HTA bodies with differing decision outcomes for the
same indication. Seven were excluded from the analysis due to
unavailability of data. The most common reasons given for rec-
ommendation of a drug were cost-effectiveness, superior efﬁcacy
to placebo, and superior efﬁcacy to comparators in 28, 14 and 13
submissions respectively. The most common reasons given for
rejection of a drug were a lack of cost-effectiveness, limitations
identiﬁed in the economic model submitted by the manufacturer,
and a lack of superior efﬁcacy to its comparators, as given in 21,
20 and 10 submissions respectively. Twenty-ﬁve of the submis-
sions highlighted the same issues pertaining to the new drug as
another HTA with a different decision outcome, but continued to
issue an alternative outcome. CONCLUSIONS: Commonly HTA
bodies focus on the relative cost-effectiveness and efﬁcacy of a
new drug. However, different HTAs place different emphases on
each aspect of a submission. Recognising the individual prefer-
ences of the appropriate body could potentially inﬂuence future
outcomes.
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OBJECTIVES: Data from randomised clinical trials (RCT) are
often considered best evidence for health technology assessments.
The objective of this study was to compare event probabilities
used in published cost-effectiveness studies to those observed in
actual clinical practice. Selective Cox-2 inhibitors (coxibs) were
used as an example. Almost all the 30 published coxib cost-
effectiveness studies used RCT data for event probabilities.
METHODS: A basic cost-effectiveness model was developed
using a decision tree. Two alternative strategies were evaluated:
prescription of a conventional NSAID or coxib. The UK General
Practice Research Database (GPRD) was used to estimate the
individual probabilities of upper gastrointestinal (GI) events
during current use of NSAID or coxib. Outcomes included upper
GI events as recorded in GPRD and hospitalisation for upper GI
events recorded in the national registry of hospitalisations (Hos-
pital Episode Statistics) linked to GPRD. Incremental prescrip-
tions costs were based on GPRD costs. RESULTS: The study
population included over 1 million patients prescribed conven-
tional NSAIDs or coxibs. Only a minority of patients used the
drugs long-term and daily (34.5% of conventional NSAIDs and
44.4% of coxibs), whereas coxib RCTs required daily use for at
least 6–9 months. The rate of upper GI events (as recorded in
GPRD) and hospitalisations during current use of conventional
NSAIDs decreased over calendar time with 5–8% per year (tests
for linear trend P-value < 0.05). The mean cost of preventing one
upper GI event as recorded in GPRD was £52 k (ranging from
£32 k with long-term daily use to £91 k with intermittent use)
and £149 k for hospitalisations. The mean costs (for GPRD
events) over calendar time were £29 k during 1990–1993 and
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